EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma

First People's Hospital of Hangzhou38 enrolled

Overview

the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.

The five year survival for pancreatic ductal adenocarcinoma (PDAC) is less than 5% in spite of the advances in management of cancers in the last few decades. Endobiliary application of radiofrequency ablation (RFA) has been developed in our unit and used in patients with unresectable bile duct and pancreatic head adenocarcinomas presenting with biliary obstruction. Various techniques of EUS-guided tumour ablation have been described, including RF ablation, photodynamic therapy, laser ablation, and ethanol injection. Endoscopic ultrasound guided RFA (EUS-RFA) of the pancreatic head using Habib EUS-RFA catheter through a 19-gauge needle was well tolerated in 5 Yucatan pigs and with minimum amount of pancreatitis .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Pancreatic Adenocarcinoma Non-resectable

Interventions

Endoscopic ultrasound guided radiofrequency ablationPROCEDURE

Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.

chemoradiotherapyRADIATION

Receive chemoradiotherapy

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients in the age group 20 to 80 years * A cytological or histological diagnosis of inoperable PDAC based on multidisciplinary review of cross sectional imaging and cytology or histology results. * Patients who have been deemed unfit for surgical resection of the PDAC subjects who are fit for surgical resection but have declined surgery will also be considered for the study * PDAC patients presenting with jaundice to be considered after a successful biliary drainage * Patients ought to be fit enough to be considered for the study (ECOG performance status 0, 1 or 2) * Patients capable of giving informed consent Exclusion Criteria: * Inability to give informed consent * Pregnancy or breast feeding * ECOG performance status 3 or 4 * Life expectancy less than 3 months * Patients with distant metastases or malignant ascites

Locations (2)

Jianfeng Yang

Hangzhou, Zhejiang, China

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

Change in tumour size as measured on EUS and or CT

The tumor size was compared before and after 60 days EUS-RFA

Time frame: 60 days

Change in serum levels of Ca 19-9

Serum levels of Ca 19-9 was compared before and after 60 days EUS-RFA

Time frame: 60 days

Secondary Outcomes

Overall survival at 6 months

Survival rate 6 months after EUS-RFA

Time frame: 6 months

Overall survival at 12 months

Survival rate 12 months after EUS-RFA

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.